Axa S.A. Has $46.89 Million Stock Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Axa S.A. cut its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 0.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 582,366 shares of the company’s stock after selling 3,859 shares during the period. Axa S.A. owned about 1.12% of PROCEPT BioRobotics worth $46,892,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PRCT. Raleigh Capital Management Inc. acquired a new stake in PROCEPT BioRobotics in the 4th quarter valued at $32,000. Thematics Asset Management bought a new stake in PROCEPT BioRobotics during the fourth quarter worth about $46,000. Signaturefd LLC boosted its position in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc bought a new position in PROCEPT BioRobotics in the fourth quarter valued at approximately $58,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of PROCEPT BioRobotics during the 3rd quarter worth approximately $64,000. Institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Morgan Stanley dropped their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Truist Financial lowered their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. Finally, Bank of America cut their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, April 25th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $90.00.

PROCEPT BioRobotics Stock Performance

Shares of NASDAQ:PRCT opened at $55.62 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -28.52 and a beta of 1.09. The company’s 50 day simple moving average is $56.75 and its 200 day simple moving average is $73.36.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.04. The company had revenue of $69.16 million during the quarter, compared to analysts’ expectations of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. PROCEPT BioRobotics’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.51) EPS. As a group, research analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In other news, CFO Kevin Waters sold 733 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares of the company’s stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Reza Zadno sold 5,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares of the company’s stock, valued at $9,875,374.20. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock worth $368,322 in the last 90 days. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).